Get started
HALOZYME THERAPEUTICS, INCHALOZYME THERAPEUTICS, INCHALOZYME THERAPEUTICS, INC

HALOZYME THERAPEUTICS, INC

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Forecast Seasonals Bonds

HALO chart


Full chart

HALO upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪127.40 B‬ MXN
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
60.70 MXN
Net income (FY)
‪4.78 B‬ MXN
Revenue (FY)
‪14.08 B‬ MXN
Shares float
‪125.86 M‬
Beta (1Y)
1.35

Employees


Employees (FY)
373
Change (1Y)
−20 −5.09%
Revenue / Employee (1Y)
‪2.22 M‬ MXN
Net income / Employee (1Y)
‪754.94 K‬ MXN

About Halozyme Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Helen I. Torley
Website
halozyme.com
Headquarters
San Diego
Founded
1998
FIGI
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

HALO news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

HALO highest yielding bonds


HALO5387960
Halozyme Therapeutics, Inc. 0.25% 01-MAR-2027
Yield to maturity
2.39%
Maturity date
Mar 1, 2027
HALO5638653
Halozyme Therapeutics, Inc. 1.0% 15-AUG-2028
Yield to maturity
−1.22%
Maturity date
Aug 15, 2028

Explore more bonds 

Sparks


Curated watchlists where HALO is featured.

See all sparks 

Frequently Asked Questions


Depending on the exchange, the stock ticker may vary. For instance, on BIVA exchange HALOZYME THERAPEUTICS, INC stocks are traded under the ticker HALO.
HALO stock has fallen by −15.36% compared to the previous week, the month change is a −15.36% fall, over the last year HALOZYME THERAPEUTICS, INC has showed a −15.36% decrease.
We've gathered analysts' opinions on HALOZYME THERAPEUTICS, INC future price: according to them, HALO price has a max estimate of 1,531.42 MXN and a min estimate of 1,020.95 MXN. Watch HALO chart and read a more detailed HALOZYME THERAPEUTICS, INC stock forecast: see what analysts think of HALOZYME THERAPEUTICS, INC and suggest that you do with its stocks.
HALO stock is 18.15% volatile and has beta coefficient of 1.35. Track HALOZYME THERAPEUTICS, INC stock price on the chart and check out the list of the most volatile stocks — is HALOZYME THERAPEUTICS, INC there?
Today HALOZYME THERAPEUTICS, INC has the market capitalization of ‪127.40 B‬, it has decreased by −10.53% over the last week.
Yes, you can track HALOZYME THERAPEUTICS, INC financials in yearly and quarterly reports right on TradingView.
HALOZYME THERAPEUTICS, INC is going to release the next earnings report on Feb 25, 2025. Keep track of upcoming events with our Earnings Calendar.
HALO earnings for the last quarter are 25.02 MXN per share, whereas the estimation was 18.88 MXN resulting in a 32.57% surprise. The estimated earnings for the next quarter are 23.96 MXN per share. See more details about HALOZYME THERAPEUTICS, INC earnings.
HALOZYME THERAPEUTICS, INC revenue for the last quarter amounts to ‪5.72 B‬ MXN, despite the estimated figure of ‪4.97 B‬ MXN. In the next quarter, revenue is expected to reach ‪6.00 B‬ MXN.
HALO net income for the last quarter is ‪2.70 B‬ MXN, while the quarter before that showed ‪1.71 B‬ MXN of net income which accounts for 57.85% change. Track more HALOZYME THERAPEUTICS, INC financial stats to get the full picture.
No, HALO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 24, 2024, the company has 373.00 employees. See our rating of the largest employees — is HALOZYME THERAPEUTICS, INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. HALOZYME THERAPEUTICS, INC EBITDA is ‪11.01 B‬ MXN, and current EBITDA margin is 50.94%. See more stats in HALOZYME THERAPEUTICS, INC financial statements.
Like other stocks, HALO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade HALOZYME THERAPEUTICS, INC stock right from TradingView charts — choose your broker and connect to your account.